|
rs121913521
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Asp816Val mutation was found in 3.5% of cases of AML and Val560Gly mutation in 1 sample with acute biclonal leukemia.
|
25247397 |
2015 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells.
|
29859988 |
2018 |
|
rs1360131632
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells.
|
29859988 |
2018 |
|
rs25487
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Collectively, the results of the present study suggest that XRCC1 Arg399Gln polymorphism might be a low-penetrant risk factor for leukemia, particularly among Asians.
|
23990457 |
2014 |
|
rs387906553
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Collectively, these data suggest that expression of V72M NE is not sufficient to induce an SCN phenotype or leukemia in mice.
|
12384420 |
2002 |
|
rs3116496
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CONCLUSIONS Our meta-analysis confirmed that rs3116496 was significantly related to cancer risk, especially in an Asian population, and was strongly correlated with the increased risk of breast cancer, leukemia and colorectal cancer.
|
30867406 |
2019 |
|
rs121913502
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Conditional deletion of IDH2/R140Q blocked 2-HG production and maintenance of leukemia stem cells, resulting in survival of the AML mice.
|
25795706 |
2015 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
|
23432162 |
2013 |
|
rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Dasatinib overrides the differentiation blockage in a patient with mutant-<i>KIT</i> D816V positive CBFβ-MYH11 leukemia.
|
29545943 |
2018 |
|
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Dasatinib overrides the differentiation blockage in a patient with mutant-<i>KIT</i> D816V positive CBFβ-MYH11 leukemia.
|
29545943 |
2018 |
|
rs1408538785
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Data from cord blood cells and leukemia cell lines suggest a role for DDX41 in preribosomal RNA processing, in which the expression of the p.R525H mutant causes a certain ribosomopathy phenotype in hematopoietic cells by suppressing MDM2-mediated RB degradation, thus triggering the inhibition of E2F activity.
|
27174803 |
2016 |
|
rs869312828
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Data from cord blood cells and leukemia cell lines suggest a role for DDX41 in preribosomal RNA processing, in which the expression of the p.R525H mutant causes a certain ribosomopathy phenotype in hematopoietic cells by suppressing MDM2-mediated RB degradation, thus triggering the inhibition of E2F activity.
|
27174803 |
2016 |
|
rs1360698171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Evaluation of xenotropic murine leukemia virus and its R426Q polymorphism in patients with prostate cancer in Kerman, southeast of Iran.
|
23098452 |
2012 |
|
rs1057519766
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
|
23878140 |
2013 |
|
rs869312953
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Finally, we also showed in an in vivo leukemia model that cells expressing JAK1(A634D) are hypersensitive to the antiproliferative and antitumorigenic effect of type I IFN, suggesting that type I IFNs should be considered as a potential therapy for ALL with JAK1-activating mutations.
|
20167706 |
2010 |
|
rs1057519753
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Further analysis showed that JAK1 V658F cooperated in vivo with PML-RARA, causing a rapidly fatal leukemia in mice.
|
21436584 |
2011 |
|
rs1042522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Further studies showed no association between leukemia risk and p53 Arg72Pro polymorphism when stratified in subtypes of leukemias, ethnicities and sources of controls.
|
23029260 |
2012 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Further studies showed no association between leukemia risk and p53 Arg72Pro polymorphism when stratified in subtypes of leukemias, ethnicities and sources of controls.
|
23029260 |
2012 |
|
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Further studies showed no association between leukemia risk and p53 Arg72Pro polymorphism when stratified in subtypes of leukemias, ethnicities and sources of controls.
|
23029260 |
2012 |
|
rs121913514
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Furthermore, dasatinib prolonged lifespan of mice bearing AE and HyC-KIT N822K-coexpressing leukemic cells and exerted synergic effects while combined with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
|
21262832 |
2011 |
|
rs7090445
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genetic analyses revealed a novel heterozygous mutation in the ETS domain of <i>ETV6</i> (c.1136T>C, p.Leu379Pro) along with absence of heterozygosity of chromosome (10)(q21.2q21.3), yielding a biallelic leukaemia risk allele in <i>ARID5B</i> (rs7090445-C).
|
31704777 |
2019 |
|
rs17886724
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotype analyses showed that two SNPs, namely rs17886724 and rs2293157 located in STAT3 and STAT5, respectively, were significantly associated with leukemia (p < 0.05 for all).
|
22126101 |
2012 |
|
rs397507476
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
|
19206169 |
2009 |
|
rs397507476
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
|
16474404 |
2006 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.
|
22985168 |
2012 |